Silence Therapeutics plc (NASDAQ: SLN) presented follow-up data from its Phase 1 SANRECO study evaluating divesiran for polycythemia vera at the European Hematology Association 2026 Annual Congress. The study enrolled 21 phlebotomy-dependent patients with the rare blood cancer.

The data showed reductions in phlebotomy use persisted after treatment ended. In the six months before treatment, patients required 80 phlebotomies total. During active treatment, only 5 phlebotomies were needed. In the 16-week follow-up period after the final dose, 4 phlebotomies were reported.

Among 14 patients with extended follow-up data, the median time to first phlebotomy was 287 days. Most patients showed improvements in symptom scores through week 34.

Divesiran was well tolerated with no dose-limiting toxicities observed. The most common side effects were mild injection-site reactions. No treatment-related serious adverse events or discontinuations due to side effects were reported.

"Data presented at EHA continue to reinforce divesiran's potential to transform the treatment paradigm for patients with polycythemia vera," said Curtis Rambaran, Chief Medical Officer at Silence Therapeutics.

The Phase 1 study evaluated divesiran at doses of 3 mg/kg, 6 mg/kg and 9 mg/kg administered every six weeks for four doses, with a 16-week follow-up period.

The ongoing Phase 2 SANRECO study is evaluating divesiran using every-six-week and every-12-week dosing regimens in 48 patients with polycythemia vera. The company expects topline results in August 2026.

Divesiran is a siRNA therapy that targets TMPRSS6, aiming to increase hepcidin production to restrict iron availability to bone marrow and reduce excessive red blood cell production. The therapy has FDA Fast Track and Orphan Drug designations for polycythemia vera.